Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • Publication number: 20190275161
    Abstract: The invention provides a CLIPTAC comprising: (a) a first portion comprising a ligand for an intracellular target protein; (b) a second portion comprising a ligand for an E3 ubiquitin ligase; and (c) a linker portion covalently coupling the first and second portions; wherein the linker comprises a covalent bond produced by a bioorthogonal click reaction between a compatible pair of reactive moieties. CLIPTAC precursor compositions and CLIPTAC precursors are also provided, together with pharmaceutical compositions comprising the CLIPTAC, CLIPTAC precursor compositions and CLIPTAC precursors, and methods of treatment using the same.
    Type: Application
    Filed: June 9, 2017
    Publication date: September 12, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Thomas Daniel HEIGHTMAN, Honorine LEBRAUD
  • Patent number: 10407415
    Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 10, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Yamashita, Tetsuya Sato, Takuya Minowa, Yusuke Hoshika, Hidekazu Toyofuku, Tetsuya Yamaguchi, Masahiro Sota, Shuuji Kawano, Takayuki Nakamura, Ryohei Eto, Takuma Ikebuchi, Kei Moriyama, Nobuaki Ito
  • Patent number: 10412089
    Abstract: A risk management system (RMS) device includes a RMS database and a RMS processor. The RMS processor includes a prescriber module to receive a request to enroll a patient in a RMS program of a therapeutic agent associated with multiple indications. The request includes a specification of at least one indication, and a confirmation of a diagnostic test conducted on the patient. The RMS processor also includes a patient module configured to generate a patient profile. The RMS processor also includes a database module configured to store the patient profile in the RMS database. The RMS processor also includes an authorization module configured to generate an authorization code indicating whether the patient is authorized to receive the therapeutic agent. The RMS processor also includes a communication module configured to transmit the authorization code to a pharmacy or a prescriber.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 10, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Frank S. Czerwiec, Amy Freedman, Keith Friend, Elaine A. O'Hara, Craig Ostroff, Marcelo De Freitas Santoro, Charles Shiner, Takeshi Watanabe, Miho Yamamoto, Christopher A. Zimmer
  • Patent number: 10393730
    Abstract: A method for measuring energy malnutrition in a liver disease test subject, a method for determining whether a liver disease test subject is in an energy malnutrition state, a method for determining the necessity of nutrition therapy for a liver disease test subject having energy malnutrition, a composition usable in these methods, and the like are provided. The method for measuring energy malnutrition in a liver disease test subject includes the steps of collecting expired air containing labeled carbon dioxide that is generated in the body of a liver disease test subject by being converted from a composition containing, as an active ingredient, glucose labeled with at least one isotope C; and determining the ratio of labeled CO2 amount to unlabeled CO2 amount, or the ratio of labeled CO2 amount to total CO2 amount in expired air.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: August 27, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Makoto Inada, Jun-ichi Kunizaki, Kazuki Tobita
  • Publication number: 20190257842
    Abstract: An object of the invention is to provide a method for assisting diagnosis of Alzheimer's disease (AD), and a detection reagent, a diagnosis kit and a diagnosis system for use in the method. Provided is a method for assisting diagnosis of AD, comprising the steps of: measuring an amount of a urine biomarker in a urine sample derived from urine collected from a subject; and determining whether the subject suffers from AD or has a high risk of developing AD based on the amount of the urine biomarker measured, wherein the urine biomarker is at least one urine protein selected from the group consisting of ApoA-I, ApoA-II, ApoA-IV, ApoB-100, ApoB-48, ApoC-I, ApoC-II, ApoC-III, ApoD, ApoE, IFITM1, IFITM2, IFITM3, NPC1, NPC2, NPC1L1, and MT.
    Type: Application
    Filed: August 3, 2017
    Publication date: August 22, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kiyonori KATSURAGI, Kiyotaka MACHIDA, Hirokazu KARIYAZONO, Ryo HIGASHIYAMA, Hironori KOBATASHI, Yoko SAIJO, Ayumi SATO
  • Publication number: 20190240215
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 8, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu INOUE
  • Patent number: 10369177
    Abstract: [Object] An object of the present invention is to provide a QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent. [Method for Achieving the Object] A QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent containing Lactobacillus ONRICb0240 (FERM BP-10065).
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: August 6, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Mina Tsubouchi, Takao Saito, Masamichi Toba, Noriyuki Kouda, Shoji Shinkai
  • Publication number: 20190218015
    Abstract: A container (1) includes: a first storage section (11) for storing a plurality of solid objects (200); a second storage section (12) provided so as to be capable of being in communication with the first storage section (11) through a predetermined communication opening (50) and also so as to be capable of being in communication with an outside space (300) through a predetermined extraction opening (100); a tray (20) having a receiving section (80) which receives one solid object (200) supplied from the first storage section (11) to the second storage section (12), the tray (20) also having a first wall section (91) capable of closing the communication opening (50), the tray (20) further having a second wall section (92) capable of closing the extraction opening (100), the tray (20) being stored in the second storage section (12); and a movement mechanism (17) for sliding the tray (20) within the second storage section (12) between a first position at which the communication opening (50) is open and the extrac
    Type: Application
    Filed: August 24, 2017
    Publication date: July 18, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kosuke TOJO, Takaaki NAKAO, Hiroshi OHNO, Shiho FUKAYA, Yoshio HARA
  • Patent number: 10350311
    Abstract: Iohexol particles, contrast agent compositions comprising iohexol particles, methods of preparing iohexol particles, and methods of administering iohexol particles are provided herein. The iohexol particles of the present invention substantially dissolve in water within about 60 seconds when tested using Modified United States Pharmacopeia Method 641.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: July 16, 2019
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Ji{hacek over (r)}í Prokop, Ivan Hlavá{hacek over (c)}ek, Petr Zahradník, Ji{hacek over (r)}í Malinak
  • Publication number: 20190167595
    Abstract: In some embodiments, a composition of matter includes aripiprazole, a metal selected from the group consisting of magnesium, zinc, sodium, lithium, iron, or alloys thereof, or combinations thereof and a copper salt selected from the group consisting of copper iodide, copper chloride, copper bromide, copper sulfate, copper formate, or combinations thereof.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Mark ZDEBLICK, Markus CHRISTEN, Nikhil PARGAONKAR, Nikolaus LEIST, Kurt SCHEINPFLUG, Patricia JOHNSON, Benedict COSTELLO
  • Publication number: 20190167672
    Abstract: Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: February 6, 2019
    Publication date: June 6, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi YAMASHITA, Yohji SAKURAI, Motoyuki MIYAMOTO, Yuichi NAKAMURA, Hideaki KURODA, Takuya MINOWA
  • Patent number: 10307419
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl -piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4 -yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer, containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 4, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu Inoue
  • Publication number: 20190161810
    Abstract: Provided are a method for assisting in determining the hematological stage of childhood acute lymphoblastic leukemia (child ALL), and an in-vitro diagnostic pharmaceutical product usable in the method. The method for assisting in determining the hematological stage of child ALL comprises the steps of (1) obtaining the mRNA level of Wilms' tumor-1 gene (WT1) in at least one of the biological samples of peripheral blood and bone marrow fluid from a test subject; (2) obtaining the GAPDH mRNA level in the biological sample; and (3) calculating an index value necessary for assisting in the determination based on the ratio of the WT1 mRNA level obtained in step (1) to the GAPDH mRNA level obtained in step (2).
    Type: Application
    Filed: July 18, 2017
    Publication date: May 30, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihide MIYAZAKI, Yukari UMEHARA, Osamu KOSAKA, Kimiyoshi SUDOU
  • Publication number: 20190151309
    Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 23, 2019
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., H. LUNDBECK A/S
    Inventors: Kenji MAEDA, Mai NAKAMURA
  • Publication number: 20190142852
    Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH2—; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).
    Type: Application
    Filed: August 30, 2018
    Publication date: May 16, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Nobuaki ITO, Hirofumi SASAKI, Kuninori TAI, Tomoichi SHINOHARA
  • Patent number: 10280467
    Abstract: A method for quantifying the expression level of human WT1 mRNA conveniently, in a short period of time, and with high sensitivity is provided. The method can be used for diagnosing cancer, such as leukemia and solid cancer, or for determining when to perform bone marrow transplantation. The method is for quantifying the expression level of human WT1 mRNA by one-step RT-PCR and comprises simultaneously subjecting the human WT1 mRNA and a housekeeping gene (mRNA) to reverse transcription and extension reactions carried out sequentially in the same vessel.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: May 7, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoko Saijo, Ryuta Ito, Daisuke Koga
  • Publication number: 20190117666
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • Publication number: 20190117648
    Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    Type: Application
    Filed: December 20, 2018
    Publication date: April 25, 2019
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Hiroshi YAMASHITA, Nobuaki ITO, Shin MIYAMURA, Kunio OSHIMA, Jun MATSUBARA, Hideaki KURODA, Haruka TAKAHASHI, Satoshi SHIMIZU, Tatsuyoshi TANAKA
  • Patent number: 10252995
    Abstract: The present invention provides a method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or a salt thereof, the method including the step of heating hydroquinone and 4-(4-trifluoromethoxyphenoxy)piperidine. This method can produce 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or a salt thereof in an industrially advantageous manner.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 9, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro Miyake, Aya Asahina, Takahiro Okada
  • Publication number: 20190099399
    Abstract: The present invention provides an ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which comprises ?-tocopherol and/or equol.
    Type: Application
    Filed: March 7, 2017
    Publication date: April 4, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tomomi UENO, Tomoko DEGUCHI, Atsuko ONODA